| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Clinical Investigations |
1 Division of Nuclear Medicine, Center for Cellular and Molecular Therapy, University Hospital of Liège, Liège, Belgium
2 Department of Rheumatology, Center for Cellular and Molecular Therapy, University Hospital of Liège, Liège, Belgium
3 Department of Bone and Joint Radiology, University Hospital of Liège, Liège, Belgium
The aim of this study was to assess synovitis by 18F-FDG PET in an individual joint analysis and in a global analysis of rheumatoid arthritis (RA) disease activity and to compare 18F-FDG PET parameters with clinical, biologic, and sonographic (US) rheumatoid parameters. Methods: Three hundred fifty-six joints were assessed in 21 patients with active RA: the knees in all subjects and either wrists as well as metacarpophalangeal and proximal interphalangeal joints in 13 patients, or ankles and the first metatarsophalangeal joints in the remaining 8 patients. PET analysis consisted of a visual identification of 18F-FDG uptake in the synovium and measurements of standardized uptake values (SUVs). Independent assessors performed the clinical and US examinations. Results: PET positivity was found in 63% of joints, whereas 75%, 79%, and 56% were positive for swelling, tenderness, and US analysis, respectively. Both the rate of PET-positive joints and the SUV increased with the number of positive parameters present (swelling, tenderness, US positivity) and with the synovial thickness. The mean SUV was significantly higher in joints where a power Doppler signal was found. In a global PET analysis, the number of PET-positive joints and the cumulative SUV were significantly correlated with the swollen and tender joint counts, the patient and physician global assessments, the erythrocyte sedimentation rate and C-reactive protein serum levels, the disease activity score and the simplified disease activity index, the number of US-positive joints, and the cumulative synovial thickness. Conclusion: 18F-FDG PET is a unique imaging technique that can assess the metabolic activity of synovitis and measure the disease activity in RA.
Key Words: 18F-FDG PET • rheumatoid arthritis • disease activity
This article has been cited by other articles:
|
|
 |
|
  S. Biswal, D. L. Resnick, J. M. Hoffman, and S. S. Gambhir Molecular Imaging: Integration of Molecular Imaging into the Musculoskeletal Imaging Practice Radiology, September 1, 2007; 244(3): 651 - 671. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. G. Radu, C. J. Shu, S. M. Shelly, M. E. Phelps, and O. N. Witte Positron emission tomography with computed tomography imaging of neuroinflammation in experimental autoimmune encephalomyelitis PNAS, February 6, 2007; 104(6): 1937 - 1942. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Rosen, L. Fayad, and R. L. Wahl Increased 18F-FDG Uptake in Degenerative Disease of the Spine: Characterization with 18F-FDG PET/CT J. Nucl. Med., August 1, 2006; 47(8): 1274 - 1280. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D Wendling, O Blagosklonov, G Streit, G Lehuede, E Toussirot, and J-C Cardot FDG-PET/CT scan of inflammatory spondylodiscitis lesions in ankylosing spondylitis, and short term evolution during anti-tumour necrosis factor treatment Ann Rheum Dis, November 1, 2005; 64(11): 1663 - 1665. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Wunder, R. H. Straub, S. Gay, J. Funk, and U. Muller-Ladner Molecular imaging: novel tools in visualizing rheumatoid arthritis Rheumatology, November 1, 2005; 44(11): 1341 - 1349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Brenner 18F-FDG PET in Rheumatoid Arthritis: There Still Is a Long Way to Go J. Nucl. Med., June 1, 2004; 45(6): 927 - 929. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
